Shots:
- The P-III ORIENT-11 study evaluates the efficacy & safety of sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT in 397 patients in a ratio (2:1) as 1L treatment for advanced or metastatic nonsq. NSCLC without sensitizing EGFR mutations or ALK rearrangements
- The results demonstrated an OS benefit with a median follow-up of 22.9mos., m-OS (not reached vs 16.8mos.). Additionally, biomarker results provide insights for patients with high MHC class-II expression
- Sintilimab is a PD-1 inhibitor, jointly developed by Eli Lilly & Innovent. Additionally, the regulatory submission is currently under review in China for sintilimab as 2L treatment of sq. NSCLC
Click here to read full press release/ article | Ref: PR Newswire | Image: Innovent
The post Eli Lilly and Innovent Report Results of Sintilimab + CT in P-III ORIENT-11 Study as 1L Treatment of NSCLC first appeared on PharmaShots.
